REPL

19.0700.83%
KX

Konstantinos Xynos

Chief Medical Officer

Dr. Konstantinos Xynos, M.D., Ph.D., M.B.A., is Member of Scientific Advisory Board of CureLab Oncology, Inc. from October 2026. Dr. Xynos is Chief Medical Officer of Replimune Group, Inc. from December 2022. Dr. Xynos joined the Replimune Group, Inc. in December 2021. He Joined Replimune in December 2021 bringing years of global biopharmaceutical experience in hematology and oncology drug development and medical affairs. Dr. Xynos joined Replimune from Deciphera where he spent years, as Vice President of Global Medical Affairs. Prior to Deciphera, he spent several years at AbbVie and few years at Astellas in increasingly senior global roles in oncology and hematology development as well as medical affairs. He completed his internal medicine residency and fellowship at the University of Athens Alexandra hospital where he served as a researcher and has practiced clinical medicine for several years. Dr. Xynos after receiving his BS in Biology at the University of Illinois in 1991, earned his MD at Aristoteleion University of Thessaloniki in 1997, his MBA at Strathclyde University in Scotland in 2013 and a Ph.D. in Cerebrovascular Disease and Stroke from the University of Athens in 2012.

Positions